We are live on ! Find out more
GWPH

GW Pharmaceuticals Plc American Depositary Shares
GWPH

Delisted

GWPH was delisted on the 4th of May, 2021.

297 hedge funds and large institutions have $5.23B invested in GW Pharmaceuticals Plc American Depositary Shares in 2021 Q1 according to their latest regulatory filings, with 116 funds opening new positions, 37 increasing their positions, 84 reducing their positions, and 94 closing their positions.

New
Increased
Maintained
Reduced
Closed

425% more funds holding in top 10

Funds holding in top 10: 421 (+17)

90% more capital invested

Capital invested by funds: $2.75B → $5.23B (+$2.48B)

23% more first-time investments, than exits

New positions opened: 116 | Existing positions closed: 94

6% more funds holding

Funds holding: 279297 (+18)

24% less call options, than puts

Call options by funds: $83M | Put options by funds: $110M

56% less repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 84

Holders
297
Holders Change
+18
Holders Change %
+6.45%
% of All Funds
5.21%
Holding in Top 10
21
Holding in Top 10 Change
+17
Holding in Top 10 Change %
+425%
% of All Funds
0.37%
New
116
Increased
37
Reduced
84
Closed
94
Calls
$83M
Puts
$110M
Net Calls
-$26.7M
Net Calls Change
-$4.85M
Name Holding Trade Value Shares
Change
Change in
Stake
NFG
226
Next Financial Group
Texas
$37K -$13K -69 -29%
RFA
227
Reilly Financial Advisors
California
$35K +$18.8K +100 +167%
PWMG
228
Prestige Wealth Management Group
New Jersey
$32K -$2.82K -15 -9%
GSAM
229
Grant Street Asset Management
Pennsylvania
$32K
WAP
230
Wealthcare Advisory Partners
Pennsylvania
$31K +$26.7K +142 New
SIS
231
Sound Income Strategies
Florida
$30.4K
NFSG
232
Newbridge Financial Services Group
Florida
$30K
ED
233
Exane Derivatives
France
$29.9K -$7.14K -38 -22%
FFC
234
First Financial Corp
Indiana
$29K
CFFP
235
Center for Financial Planning
Michigan
$28K -$10.3K -55 -30%
GEA
236
Glen Eagle Advisors
New Jersey
$26.9K -$6.77K -36 -23%
MSFP
237
Mark Sheptoff Financial Planning
Connecticut
$26K
KLWA
238
Kelly Lawrence W & Associates
California
$25K +$21.6K +115 New
CHA
239
Carmichael Hill & Associates
Maryland
$24K
RIM
240
Rockbridge Investment Management
New York
$24K +$21K +112 New
FCA
241
FinTrust Capital Advisors
South Carolina
$23K
FEG
242
Financial Enhancement Group
Indiana
$22K
MAWCM
243
Mine & Arao Wealth Creation & Management
California
$22K
OIA
244
Optimum Investment Advisors
Illinois
$22K
RWB
245
RMR Wealth Builders
New Jersey
$22K
SOW
246
State of Wyoming
Wyoming
$22K +$19.4K +103 New
FHC
247
First Horizon Corporation
Tennessee
$21K
CFA
248
Carroll Financial Associates
North Carolina
$20K
Bessemer Group
249
Bessemer Group
New Jersey
$18K +$14.5K +77 +1,283%
QCG
250
Quadrant Capital Group
Ohio
$16K +$13.5K +72 New

GWPH Hedge Fund Activity: Q1 2021 in Review

297 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in GW Pharmaceuticals Plc American Depositary Shares (GWPH) for Q1 2021, worth a combined $5.23B — up 90% from $2.75B a quarter earlier.

Buyers outnumbered sellers: 116 funds opened new GWPH positions and 94 closed out — a net gain of 22 holders — while 37 added to existing stakes and 84 trimmed.

The largest buyer was Pentwater Capital Management, opening a new position worth an estimated $395M. The largest seller was Capital Research Global Investors, cutting an estimated $694M.

  • 297 institutional investors held GW Pharmaceuticals Plc American Depositary Shares (GWPH) as of Q1 2021, up from 279 in Q4 2020.
  • Funds reported $5.23B of GW Pharmaceuticals Plc American Depositary Shares stock for Q1 2021, up 90% quarter-over-quarter.
  • 116 funds opened new GW Pharmaceuticals Plc American Depositary Shares positions in Q1 2021 and 94 closed out, a net change of +22 holders.
  • The largest GW Pharmaceuticals Plc American Depositary Shares buyer in Q1 2021 was Pentwater Capital Management, an estimated $395M added.
  • The largest GW Pharmaceuticals Plc American Depositary Shares seller in Q1 2021 was Capital Research Global Investors, an estimated $694M sold.

Based on aggregated 13F filings for Q1 2021.